ArticleFrontiers in immunology2026
Dysregulation of the cytotoxic-humoral axis and expansion of regulatory T cells in anti-TIF1γ- positive dermatomyositis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dermatomyositis (DM), particularly the anti-TIF1γ‑positive subtype, is associated with a substantially elevated risk of malignancy. However, the peripheral immune landscape of this autoantibody-defined subset, especially in patients without concurrent cancer, remains incompletely understood. Methods: We performed single‑cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) from five patients with anti‑TIF1γ‑positive DM (the subtype with the highest malignancy risk) and compared their profiles with those of two other DM subtypes: anti‑MDA5‑positive DM (intermediate malignancy risk) and anti‑synthetase syndrome (ASyS, low malignancy risk). Results: All three subtypes exhibited profound immune remodeling, characterized by reduced frequencies of cytotoxic lineage cells. Anti‑TIF1γ‑positive DM showed a compensatory shift toward humoral immunity, with increased B‑lineage cells, whereas classical monocyte elevation was specific to the anti‑MDA5‑positive DM and ASyS subtypes. Notably, anti‑TIF1γ‑positive DM was uniquely distinguished by an increased frequency of immunosuppressive regulatory T (Treg) cells, a finding validated by immunohistochemistry in patient skin tissue. Conclusion: These results delineate a peripheral immunological signature of anti‑TIF1γ‑positive DM, marked by compromised cytotoxic surveillance, aberrant humoral responses, and selective Treg enrichment. We hypothesize that this Treg elevation may contribute to an immunosuppressive milieu that favors malignancy, although this mechanism remains speculative and requires functional validation in prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.